People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Novo Nordisk, Pfizer And J&J Fall In Premarket The trial showed that once-weekly Sogroya was non-inferior to the once-daily growth hormone Norditropin (somatropin) in improving yearly growth rate ...

N) today presented data from the Phase III REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

Novo Nordisk presents positive results from phase 3 REAL8 basket study of once-weekly Sogroya at the joint Congress of ESPE and ESE: Bagsværd, Denmark Tuesday, May 13, 2025, 10:0 ...

2 Novo Nordisk stressed that non-adherence to daily growth hormone injections—often due to discomfort, inconvenience, or disruption—can significantly impact outcomes, with one study showing a 6.1 cm ...